Bionano Genomics (BNGO) Peer Comparison

$1.21

$-0.02 (-1.23%)

As on 01-Sep-2026 15:37EDT

Market cap

$14 Mln

Revenue (TTM)

$30 Mln

P/E Ratio

--

P/B Ratio

0.5

Div. Yield

0 %

Edit

	Bionano Genomics (BNGO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	14	12,753	10,906	9,948	9,762
Revenue ($ Mln)	30	1,505	613	785	2,589
Net Profit ($ Mln)	-32.16	160.59	-188.05	41.54	222.40
Net Margin (%)	-106.58	10.67	-30.68	5.29	8.59
RoE (%)	-84.60	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.81	44.47
Price-To-Book	0.45	8.41	16.38	4.86	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Bionano Genomics (BNGO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	30.18	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	15.84	483.98	127.96	384.30	1,245.50
Gross Profit	6.26	942.44	393.22	347.62	1,343.60
Operating Expenses	46.52	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-32.19	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-32.10	203.83	-192.83	52.15	350.40
Provision for Tax	0.07	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-32.16	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Bionano Genomics (BNGO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	31.61	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	5.95	210.18	135.71	705.49	2,116.80
Current Liabilities	10.04	233.78	102.33	132.66	961.30
Total Liabilities	73.58	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Bionano Genomics (BNGO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	22.71	630.60	404.74	1,749.63	7,231.50
Current Assets	24.88	1,344.12	515.78	1,200.55	3,020.50
Total Assets	73.58	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	6.70	212.71	102.84	690.94	1,203.70
Net Current Assets	0.00	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Bionano Genomics (BNGO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	-16.35	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-12.75	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	24.04	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Bionano Genomics (BNGO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-46.30	11.76	-22.53	1.79	8.98
ROE (%)	-84.60	10.86	-28.10	1.97	3.04
ROA (%)	-37.26	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-105.66	13.63	-30.58	9.87	-5.99
Net Margin (%)	-106.58	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Bionano Genomics (BNGO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	10.03	17.55	41.55	16.49	1.37
EBIT Growth (%)	56.94	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	56.73	8.72	-102.66	400.42	-30.32
EPS Growth (%)	91.68	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-79.24	17.33	-12.65	2.16	2.19

Valuation Ratios

	Bionano Genomics (BNGO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-0.62	68.93	-34.59	189.42	--
Price / Book Value	0.37	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-0.62	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Bionano Genomics (BNGO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.00	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.03	0.01	0.00	0.01	0.06
Current Ratio	2.48	5.75	5.04	9.05	3.14
Quick Ratio	1.96	3.86	4.46	7.64	2.33
Interest Coverage	-149.69	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Bionano Genomics (BNGO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	14.47	12.65	22.67	20.09	17.06
Asset Turnover	0.35	0.74	0.59	0.26	0.24
Receivable days	63.89	46.54	60.95	72.41	65.39
Inventory Days	136.00	331.92	193.84	146.53	221.09
Payable days	103.03	26.16	60.19	29.05	37.02
Cash Conversion Cycle	96.87	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly